86499-35-6

Basic information

• Product Name: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one
• Synonyms: 3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENAZEPIN-2-ONE;3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE HYDROCHLORIDE;3-AMINO-1,3,4,5-TETRAHYDRO-2H-1-BENZAZEPIN-2-ONE;3-AMINO-1,3,4,5-TETRAHYDRO-BENZO[B]AZEPIN-2-ONE;3-Amino-2,3,4,5-tetrahydro-2-oxo-2H-1-benzazepine;3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one;Benazepril Intermediate;3-amino-1,3,4,5-tetrahydro-2H-benzaone-2-one
• CAS NO: 86499-35-6
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.22
• Product Categories: pharmacetical
• Mol File: 86499-35-6.mol
• Article Data: 22

Chemical Properties

• Melting Point: 193-195 °C
• Boiling Point: 377.5 °C at 760 mmHg
• Flash Point: 182.1 °C
• Appearance: /
• Density: 1.143 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.57±0.40(Predicted)
• CAS DataBase Reference: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(86499-35-6)
• EPA Substance Registry System: 3-Amino-2,3,4,5-Tetrahydro-1H-1-benzazepin-2-one(86499-35-6)

Safety Data

• Hazardous Substances Data: 86499-35-6(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 50, p. 3408, 1985 DOI: 10.1021/jo00218a034

InChI:InChI=1/C10H12N2O.ClH/c11-8-6-5-7-3-1-2-4-9(7)12-10(8)13;/h1-4,8H,5-6,11H2,(H,12,13);1H

Upstream product

• 97278-68-7 3-azido-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepine 
• 19832-98-5 4-methyl-3,4-dihydro-2H-naphthalen-1-one 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 7440-44-0 pyrographite 
• 86499-96-9 3-bromo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 88372-41-2 (+/-)-2-amino-4-(2-amino-phenyl)-butyric acid 
• 7772-99-8 stannous chloride 
• 68253-36-1 1-tetralone oxime 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 140700-64-7 3-iodo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 

Downstream Products

• 145485-21-8 6-t-Butoxycarbonylamino-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-hexanamide 
• 145485-23-0 1-t-Butoxycarbonylamino-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-cyclohexanecarboxamide 
• 86499-26-5 3-amino-1-benzyloxycarbonylmethyl-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one 
• 86499-51-6 3-benzyloxycarbonylamino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one 
• 86499-69-6 1,1-dimethylethyl (2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl)carbamate 
• 1414963-26-0 N-(3-(3-fluorophenyl)-1-((R)-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-1-oxopropan-2-yl)-2-trimethylstannanylbenzamide 
• 950509-59-8 (R)-3-tritylamino-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one 
• 959845-01-3 (R)-3-tritylamino-1-isopropyl-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one 
• 1414963-22-6 C₂₇H₃₄FN₃O₄ 
• 1414963-23-7 2-amino-3-(2-fluorophenyl)-N-((R)-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)propanamide 
• 1414963-24-8 N-(3-(3-fluorophenyl)-1-((R)-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-1-oxopropan-2-yl)-2-iodobenzamide 
• 97278-68-7 3-azido-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepine 

Relevant articles and documents

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer''s disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer''s disease both prophylactically and therapeutically with such pharmaceutical compositions.